The major ones are ECTRIMS (mid-October), ACTRIMS (early June) and the UK MS Society Research Conference (mid-June). Links as follows:
Ectrims receives a huge number of research papers / results of trials. Topics being discussed this year are:
- Pathogenesis of MS: what have we learned during the last decades?
- CNS repair and neuroprotection
- Immunosuppression revisited: benefits and risks
- Early MS: to treat or not to treat?
- MRI: reliable surrogate marker?
The following presentations being given are:
12th Annual Meeting of ACTRIMS
Emerging Therapies in Multiple Sclerosis
Therapeutic Monoclonal Antibodies: An Overview
Professor Herman Waldmann
Natalizumab Therapy in Multiple Sclerosis
Olaf Stuve, MD, PhD
Use of Daclizumab in Multiple Sclerosis
Bibi Bielekova, MD
Studies on Rituximab in the Treatment of Multiple Sclerosis
Emmanuelle Waubant, MD, PhD
Beyond the Monoclonals: Promising Oral Agents and Neuroprotective Strategies Peter Calabresi, MD
Designing Rational Clinical Trials for New and Emerging Therapies
Fred Lublin, MD
It's encouraging to see that the presentations are moving beyond the current injectibles and that more attention is being paid to neuro-protection. Mr Z, a big fan of Tysabri, will be pleased that monoclonal antibodies feature strongly.